Celltrion is expanding to expand the drug’s market share with the addition of Remsima SC’s dosing regimens that followed the EMA’s recommendation for the drug’s marketing authorization.

The autoimmune disease treatment Remsima SC recently received final approval from the European Commission (EC) for the 'allowance of additional dosing regimens and dose escalation.’

Remsima SC is the world's first subcutaneous (SC) formulation of infliximab (Remicade), an autoimmune disease treatment that was previously available only as an intravenous (IV) formulation.

The approval comes about a month after the European Medicines Agency's (EMA) Committee for Medicinal Products for Hu